Integra LifeSciences Holdings Corp Stock
There is an upward development for Integra LifeSciences Holdings Corp compared to yesterday, with an increase of €0.30 (2.680%).
Currently there is a rather negative sentiment for Integra LifeSciences Holdings Corp with 1 Buy predictions and 4 Sell predictions..
With a target price of 10 € there is a slightly negative potential of -13.04% for Integra LifeSciences Holdings Corp compared to the current price of 11.5 €.
Pros and Cons of Integra LifeSciences Holdings Corp in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Integra LifeSciences Holdings Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Integra LifeSciences Holdings Corp | 2.680% | -2.609% | 7.692% | -50.877% | -47.170% | -79.065% | -76.471% |
| Icu Medical Inc. | 2.460% | -1.613% | 2.521% | -19.737% | -17.007% | -17.007% | -23.750% |
| Bio-Rad Labs Inc. A | 1.740% | -1.966% | 1.317% | -16.522% | -14.263% | -31.823% | -41.201% |
| Neogen Corp. | 6.310% | 16.505% | 8.108% | -52.000% | -50.000% | - | - |
Comments
Integra LifeSciences (NASDAQ:IART) had its price target lowered by analysts at Citigroup Inc. from $12.00 to $11.00. They now have a "sell" rating on the stock.
Show more
Ratings data for IART provided by MarketBeat
Integra LifeSciences (NASDAQ:IART) had its price target raised by analysts at JPMorgan Chase & Co. from $12.00 to $13.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for IART provided by MarketBeat
Integra LifeSciences (NASDAQ:IART) had its "sell" rating reaffirmed by analysts at Citigroup Inc..
Show more
Ratings data for IART provided by MarketBeat
News
Integra (IART) Q2 Revenue Beats by 5%
Integra LifeSciences (NASDAQ:IART), a medical technology company specializing in neurosurgery, reconstructive, and tissue technologies, released its results for Q2 2025 on July 31, 2025. The most
